North American Report

Frontotemporal Dementia Clinical and Non-Clinical Studies, Therapeutic Pipeline Assessment, and Emerging Therapies | Key Companies – TauRx Therapeutics, Alector, Neurimmune, Biogen, and Others

 Breaking News
  • No posts were found

Frontotemporal Dementia Clinical and Non-Clinical Studies, Therapeutic Pipeline Assessment, and Emerging Therapies | Key Companies – TauRx Therapeutics, Alector, Neurimmune, Biogen, and Others

October 20
20:44 2021
Frontotemporal Dementia Clinical and Non-Clinical Studies, Therapeutic Pipeline Assessment, and Emerging Therapies | Key Companies - TauRx Therapeutics, Alector, Neurimmune, Biogen, and Others
Delveinsight Business Research LLP
Frontotemporal Dementia Pipeline Insight, 2021″ report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Frontotemporal Dementia Market.

The Frontotemporal Dementia Pipeline report embraces in-depth commercial and clinical assessment of the Frontotemporal Dementia pipeline products from the pre-clinical developmental phase to the marketed phase. 

The report covers a detailed description of the drug including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Frontotemporal Dementia collaborations, mergers, acquisition, funding, designations, and other product-related details.

Frontotemporal Dementia Pipeline Analysis

Frontotemporal Dementia Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Frontotemporal Dementia with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for the Frontotemporal Dementia Treatment.

  • Frontotemporal Dementia key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Frontotemporal Dementia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Frontotemporal Dementia market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Frontotemporal Dementia Therapeutics Landscape

As per the DelveInsight, the dynamics of the Frontotemporal dementia market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the disease, incremental healthcare spending across the world, and also the expected launch of emerging therapies during the forecast period. Recent advances also suggest that there is an array of potential novel therapeutic targets, although data concerning their effectiveness are still preliminary.

Companies across the globe are working toward the development of new treatment therapies for frontotemporal dementia, but few companies have made it to the clinical stage of development.

Some of the Key Companies in the Frontotemporal Dementia Market Include:

  • TauRx Therapeutics

  • Alector

  • Neurimmune

  • Biogen

And many others.

Frontotemporal Dementia Therapies covered in the report includes:

  • LMTX

  • AL001

  • NI205

And many others.

Request for Sample Pages @ Frontotemporal Dementia Emerging Therapies and Key Companies

Report Highlights

  • A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Frontotemporal Dementia.    

  • In the coming years, the Frontotemporal Dementia market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market. 

  • The companies and academics are working to assess challenges and seek opportunities that could influence Frontotemporal Dementia Research & Development. The therapies under development are focused on novel approaches to treat/improve the disease condition.

  • A detailed portfolio of major pharma players who are involved in fueling the Frontotemporal Dementia treatment market. Several potential therapies for Frontotemporal Dementia are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Frontotemporal Dementia market size in the coming years.  

  • Our in-depth analysis of the Frontotemporal Dementia pipeline assets (in early-stage, mid-stage, and late stage of development) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities. 

Download Sample Pages @ Frontotemporal Dementia Therapeutics Pipeline

Table of Content

1. Report Introduction

2. Frontotemporal Dementia 

3. Frontotemporal Dementia Current Treatment Patterns

4. Frontotemporal Dementia – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Frontotemporal Dementia Late Stage Products (Phase-III)

7. Frontotemporal Dementia Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Frontotemporal Dementia Discontinued Products

13. Frontotemporal Dementia Product Profiles

14. Frontotemporal Dementia Key Companies

15. Frontotemporal Dementia Key Products

16. Dormant and Discontinued Products

17. Frontotemporal Dementia Unmet Needs

18. Frontotemporal Dementia Future Perspectives

19. Frontotemporal Dementia Analyst Review  

20. Appendix

21. Report Methodology

*The table of contents is not exhaustive; the final content may vary. 

Visit to get the sample report:

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States